ArticleInternational urology and nephrology2016
The accuracy of the anti-phospholipase A2 receptor antibody in the diagnosis of idiopathic membranous nephropathy: a comparison of different cutoff values as measured by the ELISA method.
Article in International urology and nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- PLA2R autoantibodies, a multifaceted biomarker in nephrotic syndrome and membranous nephropathy.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Pooled it
- The Effect of Mycophenolate Mofetil versus Cyclosporine as Combination Therapy with Low Dose Corticosteroids in High-risk Patients with Idiopathic Membranous Nephropathy: a Multicenter Randomized Trial.Journal of Korean medical science · 2018Trial
- Diagnostic value of renal biopsy in anti-phospholipase A2 receptor antibody-positive patients with proteinuria in China.Scientific reports · 2024Article
- Measurement of urinary exosomal phospholipase A2 receptor is a sensitive method for diagnosis of PLA2R-associated membranous nephropathy.Clinical kidney journal · 2024Article
- The cutoff value and prognosis of anti-PLA2R antibody for idiopathic membranous nephropathy: a single-center retrospective study in China.Renal failure · 2023Article
- Determination of Anti-Phospholipase A2 and Anti-Thrombospondin Type 1 Domain-Containing Protein 7A in Latin Patients with Membranous Nephropathy.Diagnostics (Basel, Switzerland) · 2022Article
- Anti-phospholipase A2 receptor antibody screening in nephrotic syndrome may identify a distinct subset of patients with primary membranous nephropathy.International urology and nephrology · 2022Article
- The Role of Anti-PLAInternational journal of environmental research and public health · 2022Review
- The optimal anti-phospholipase A2 receptor cutoff for the diagnosis of idiopathic membranous nephropathy: a single-center retrospective study.The Korean journal of internal medicine · 2022Article
- Rapid, quantitative, and high-sensitivity detection of anti-phospholipase A2 receptor antibodies using a novel CdSe/ZnS-based fluorescence immunosorbent assay.Scientific reports · 2021Article
- A New Chemiluminescence Immunoassay for Phospholipase AKidney international reports · 2021Article
- Development of a Standardized Chemiluminescence Immunoassay for the Detection of Autoantibodies Against Human M-Type Phospholipase A2 Receptor in Primary Membranous Nephropathy.Kidney international reports · 2020Article
- Comparison of measurements of anti-PLA2R antibodies in Japanese patients with membranous nephropathy using in-house and commercial ELISA.Clinical and experimental nephrology · 2019Article
- Serum Levels of BAFF and APRIL Predict Clinical Response in Anti-PLA2R-Positive Primary Membranous Nephropathy.Journal of immunology research · 2019Article
- Diagnostic Test Accuracy of Serum Anti-PLA2R Autoantibodies and Glomerular PLA2R Antigen for Diagnosing Idiopathic Membranous Nephropathy: An Updated Meta-Analysis.Frontiers in medicine · 2018Article
- Ultrasensitive Quantitation of Anti-Phospholipase A2 Receptor Antibody as A Diagnostic and Prognostic Indicator of Idiopathic Membranous Nephropathy.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimRecent studies have revealed that anti-phospholipase A2 receptor antibodies (aPLA2R-ABs) may play a role in the diagnosis of idiopathic membranous nephropathy (IMN). We will investigate the application of an aPLA2R-AB with different cutoff values for diagnosing IMN.
methodsFrom August 2014 to December 2014, patients with proteinuria greater than 1 g/day were screened at the First Affiliated Hospital of Zhengzhou University. Patients were divided into the IMN and non-IMN groups based on the results of renal biopsy. The sensitivity, specificity, and receiver operating characteristic (ROC) curve of aPLA2R-AB for diagnosing IMN were analyzed.
resultsA total of 229 patients (113 males, average age of 45.3 ± 15.8 years) were enrolled in this study, and 118 patients were diagnosed with IMN. The sensitivity/specificity of aPLA2R-AB in the diagnosis of IMN was 65.3/97.3 %, 60.2/97.3 %, and 45.8/97.3 % for the different cutoff values (14, 20, and 40 RU/ml). The area of the ROC curve was 0.87.
conclusionAnti-PLA2R-AB with a cutoff value of 14 RU/ml based on the ELISA method plays an important role in the diagnosis of IMN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.